| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 7.876 | 7.135 | 5.809 | 0 | 4.726 | 4.401 | 3.901 | 4.167 | 4.593 | 5.707 |
| Total Income - EUR | 7.876 | 7.135 | 5.809 | 0 | 4.726 | 4.401 | 3.901 | 4.167 | 4.593 | 5.720 |
| Total Expenses - EUR | 6.482 | 5.634 | 4.741 | 0 | 3.845 | 3.418 | 3.151 | 3.525 | 3.868 | 5.073 |
| Gross Profit/Loss - EUR | 1.394 | 1.501 | 1.068 | 0 | 881 | 983 | 749 | 642 | 724 | 646 |
| Net Profit/Loss - EUR | 1.157 | 1.287 | 894 | 0 | 745 | 859 | 635 | 532 | 621 | 554 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Pirmabionyc Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2.524 | 2.498 | 2.456 | 0 | 2.364 | 2.319 | 2.268 | 2.275 | 2.268 | 2.255 |
| Current Assets | 4.298 | 4.196 | 4.826 | 0 | 6.177 | 6.129 | 6.715 | 7.189 | 7.758 | 5.919 |
| Inventories | 4.099 | 3.839 | 4.474 | 0 | 5.014 | 5.860 | 6.482 | 6.949 | 6.848 | 5.001 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29 |
| Cash | 199 | 357 | 351 | 0 | 1.163 | 270 | 234 | 240 | 910 | 889 |
| Shareholders Funds | 1.312 | 2.586 | 3.436 | 0 | 4.965 | 5.730 | 6.238 | 6.789 | 7.389 | 7.902 |
| Social Capital | 90 | 89 | 88 | 0 | 84 | 83 | 81 | 81 | 81 | 80 |
| Debts | 5.509 | 4.108 | 3.846 | 0 | 3.586 | 2.728 | 2.755 | 2.685 | 2.646 | 281 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4711 - 4711" | |||||||||
| CAEN Financial Year |
4711
|
|||||||||
Comments - Pirmabionyc Srl